Key Takeaways
- Reset quarter, recovery promised: Revenue declined sequentially as the company absorbed a post-acquisition operational reset, including a INR40 crore non-cash ESOP charge and the discontinuation of the trade generics business. Management expects normalization to begin in Q1.
- India branded business is the bedrock: Stripping out the exited trade generics line, the core branded business grew 8% in Q4 and management is confident of accelerating it back to double digits.
- Gross margin jumped on mix shift: Gross margin improved to ~70% from 66% YoY, helped by the trade generics exit and a favorable product mix, though management wants one more quarter before guiding on a full-year settlement level.
- International and CDMO businesses hit air pockets: International formulations de-grew 9% on policy harmonization and shipping constraints, while CDMO fell 22% on a high base and execution delays. Both are expected to recover from Q1/Q2.
- What to watch next quarter: Whether the promised India branded acceleration materializes, the pace of CDMO contract execution, and any color on field force rationalization post-merger.
The Post-Acquisition Reset
- Change in control: Torrent Pharma acquired a controlling stake on 21st January 2026, making Q4 the first quarter under the new parent. The period was used to align JB's practices with Torrent's across distribution, trade terms, credit policies, and sales closing.
- One-off costs: Non-cash ESOP charges of INR40 crores weighed on the quarter's reported profitability.
- Merger progress: Shareholder approvals for the merger of JB Pharma with Torrent are in hand, and the hearing date is set for the second week of June. Management expects the merger to become effective within one to two months.
- Distribution optimization complete: The distribution network has already been optimized and should start showing margin improvement visibility from April.
Aman Mehta: "I think the positive surprises definitely would be that the brands in the India business in particular continue to give us confidence that, you know, these are such widely established and recognized brands and familiarity is so high that in a merged entity it would certainly be possible to accelerate the growth further."
India Business: Trade Generics Exit Resets the Base
- The headline slowdown is mechanical: The sequential growth decline was driven by the discontinuation of the trade generics business. Without it, the branded business grew 8% for the quarter.
- Trade generics shelved: Management does not intend to reinvest or add products in trade generics until it finds a good product mix, which may take time. The focus is exclusively on growing the branded business.
- Recovery timeline: Double-digit or low-teens growth for the India business may take a couple of quarters, but management is already seeing positive signs. From next year, the reported base will be clean of the trade generics drag.
- Chronic coverage gap as opportunity: The gap in chronic and cardiac brand coverage between JB and Torrent is seen as a revenue synergy opportunity, with early signs already visible and more color promised in subsequent quarters.
- Field force attrition: Attrition in the JB field force was significantly higher than Torrent's and continues to remain so. Management declined to comment on whether the combined sales force number would come down post-merger, deferring any specifics to Q1 onwards.
International & CDMO: Two Drags, Two Recoveries
- International formulations de-grew 9%: The decline came from alignment of JB's sales closing practices, harmonized credit policies, and rationalization of in-market inventory with Torrent's standards, plus container shipment constraints to the Middle East and Asia.
- International recovery path: Single-digit growth should resume potentially from Q1 but more likely from Q2. West Asia faces some Q1 uncertainty from container constraints, but Q2 onwards should be on track.
- International attrition minimal: JB runs a distributor-led model with direct subsidiaries only in South Africa (zero overlap with Torrent) and Russia (some overlap, so some rationalization is expected). Attrition has been minimal.
- CDMO declined 22%: The drop reflects a high base in the year-ago quarter plus execution delays on contracts with top-five OTC customers. The bottleneck is a lean development organization that needs additional resources to accelerate new product delivery into revenue.
- CDMO growth drivers intact: Management insists flat is not normal for this business. New projects and contracts are on hand with top global customers (Innova, Kenvue, P&G, Reckitt). The task is to increase wallet share with existing customers and expand the geographic footprint to large customers where JB is not present.
Sanjay Gupta: "So essentially, they bring to you new products or new ideation and you have to develop and manufacture these products and supply to them. So JB has some delays in execution of these contracts which are on hand. So our job is to accelerate the delivery of these new products so that they can come into revenue quicker rather than later."
Synergies: Revenue and Procurement Starting to Flow
- Revenue synergies: Expected to begin in probably the next couple of quarters, with the chronic brand coverage gap between the two companies flagged as a specific opportunity.
- Procurement synergies: Already playing out from April with a strong positive impact, though management cautions that external geopolitical factors may prevent the full impact from being visible in the current year.
- Distribution optimization: Completed and expected to start contributing to margin improvement visibility from April.
Margins: Gross Margin Up, Full-Year Guidance Deferred
- Gross margin improved to ~70% from 66% YoY, driven partly by the trade generics reset and partly by product mix.
- Guidance on hold: Management wants to wait for one more quarter (Q1) before giving guidance on where gross margin will settle for the full year, as the integration effects are still flowing through.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India branded business growth | Accelerate by a few percentage points from current trajectory; return to double-digit growth | Couple of quarters |
| International business recovery | Return to single-digit growth | Potentially Q1, more likely Q2 |
| West Asia normalization | Container constraints ease, business on track | Q2 onwards |
| Merger effectiveness | Hearing in second week of June; merger effective | One to two months max |
| CDMO momentum | Positive momentum; flat is not normal | On a 12-month basis |
| Revenue synergies | Begin to materialize | Next couple of quarters |
| Procurement synergies | Strong positive impact already from April; full impact may be muted by geopolitics in current year | From April |
| Distribution optimization margin impact | Visibility in margin improvement | From April |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹904 cr, de-growth of 5% YoY |
| Gross margin | ~70%, up from 66% in Q4 FY25 |
| Adjusted EBITDA | ₹241 cr, flat YoY after adjusting for one-offs |
| Adjusted EBITDA margin | ~27%, up ~2 ppt from 25% in Q4 FY25 |
| Reported net profit | ₹101 cr |
| Adjusted net profit | ₹150 cr, after adjusting for one-offs of ₹40 cr including non-cash ESOP charges |
| India business revenue | ₹526 cr, 2% YoY growth |
| India branded business growth | 8% YoY |
| International formulations revenue | ₹259 cr, de-growth of 9% YoY |
| CDMO business revenue | Declined 22% YoY due to high base |
| Net cash | ~₹1,200 cr as of FY26 |
| India field force | ~2,500 MRs |
| Final dividend | ₹9.3 per equity share of ₹1 each for FY26 |